News >

DLBCL Landscape Shifts Dramatically With Axicabtagene Ciloleucel FDA Approval

Gina Columbus @ginacolumbusonc
Published: Tuesday, Oct 24, 2017

Reem Karmali, MD

Reem Karmali, MD
The non–Hodgkin lymphoma landscape recently underwent a major transformation, as researchers in the field saw the FDA approval of axicabtagene ciloleucel (axi-cel; Yescarta), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy for transplant-ineligible patients with relapsed or refractory disease.

on Hematologic Malignancies, Karmali, assistant professor of medicine (hematology and oncology), Feinberg School of Medicine, Northwestern University, discussed ongoing key trials of CAR T-cell therapy, the chronic safety concerns with the treatment, and what combinations have the most potential.

OncLive: There have been several developments in CAR T-cell therapy over the last few months. What did you share in your presentation?

Karmali: We went through a little bit of an overview of immunotherapy as a segue to CAR T-cell therapy, and then, with respect to CAR T cells, we talked about the construct itself, its mechanism of action, and then we spoke about some of the key clinical trials for CAR T-cell therapy—specifically focusing on some of the encouraging results we are seeing in DLBCL.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell TherapyAug 30, 20191.5
Publication Bottom Border
Border Publication
x